Summary
People with Down Syndrome (Trisomy 21) often have multiple ocular issues, including cataracts. Beta-amyloid and its aggregates, which are derived from a cleavage product of a protein located on Chromosome 21, accumulate in the eye (retina and lens). We propose to use an in-house technology to discover nanobodies that can be used as probes to detect, characterize, and potentially sequester/dissolve beta-amyloid in the eye, improving health and preventing such degeneration for people with Down Syndrome.